Actively Recruiting
Study of Placental Growth Factor PlGF as a Biomarker for Brain Lesions in Babies Exposed to Alcohol Before Birth
Led by University Hospital, Rouen · Updated on 2026-02-06
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the role of Placental Growth Factor PLGF as a biomarker to detect brain lesions caused by alcohol exposure during pregnancy. This study focuses on how these brain lesions might relate to developmental disorders and disabilities, which can be best diagnosed at ages 2 and 6. The trial includes pregnant women with and without alcohol consumption during pregnancy to better understand PLGFs diagnostic value for fetal brain damage. Participants are divided into two groups those with chronic or binge alcohol consumption during pregnancy and those with no alcohol exposure. Samples of maternal blood before delivery, cord blood after delivery, and placenta tissue will be collected. Behavioral and developmental assessments, including parental questionnaires and psychological development scales such as WPPSI-IV, NEPSY, Conners, and SCQ, will be administered to evaluate the childs development. Participants will undergo neurological evaluations on the day of birth, followed by neurodevelopmental assessments at 2 and 6 years of age. These include standardized tests and questionnaires to assess cognitive, social, and developmental outcomes. PLGF levels in maternal blood, placenta, and umbilical cord blood will be measured about four months after sample collection. The total follow-up period extends through the childs sixth year to monitor long-term developmental outcomes.
CONDITIONS
Brief Title
In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions
Research Team
P
POURCHER
B
BLOT
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here